<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308148</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10029</org_study_id>
    <nct_id>NCT04308148</nct_id>
  </id_info>
  <brief_title>Does Medical Cannabis Reduce Opioid Use in Adults With Pain</brief_title>
  <acronym>ReLeaf-E</acronym>
  <official_title>Does Medical Cannabis Reduce Opioid Use in Adults With Pain: An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laura and John Arnold Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vireo Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine how medical cannabis use affects opioid analgesic use. This landmark&#xD;
      study will be among the first to examine the effect of medical cannabis with different&#xD;
      THC/CBD content on opioid use as well as adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine how medical cannabis use affects opioid analgesic use, with&#xD;
      particular attention to THC/CBD content and adverse events. We will enroll adults with (a)&#xD;
      severe or chronic neuropathic or joint pain, (b) prescribed opioid analgesic use, (c) active&#xD;
      certification for medical cannabis, and (d) intends to have soft gel capsule products&#xD;
      dispensed at Vireo (medical cannabis dispensary) (including a high THC:low CBD product, an&#xD;
      equal THC:CBD product, and a low THC:high CBD product). Over the 14 weeks, data sources will&#xD;
      include questionnaires; medical, pharmacy, and Prescription Monitoring Program (PMP) records;&#xD;
      and urine samples. The primary independent variable will be type of soft gel capsule product,&#xD;
      and the primary outcome will be cumulative opioid analgesic dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid analgesic use</measure>
    <time_frame>Opioid analgesic use will be weekly cumulative dose of opioid analgesics over 14 weeks.</time_frame>
    <description>The primary outcome will be opioid analgesic use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Adverse events will be over 14 weeks</time_frame>
    <description>(e.g. Cannabis use disorder, illicit drug use, diversion of medical cannabis, accidents and injuries)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Opioid Use</condition>
  <condition>Marijuana</condition>
  <condition>Chronic Pain</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with chronic pain, who are taking opioids and are actively certified for medical&#xD;
        cannabis in New York.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  English or Spanish fluency&#xD;
&#xD;
          -  Actively certified for medical cannabis&#xD;
&#xD;
          -  No medical cannabis dispensed or used within the previous 90 days&#xD;
&#xD;
          -  Intends to have a soft-gel capsule product dispensed at Vireo&#xD;
&#xD;
          -  Medical cannabis qualifying conditions or complications of &quot;chronic or severe pain&quot; or&#xD;
             &quot;pain that degrades health and functional capability as an alternative to opioid use&#xD;
             or substance use disorder&quot;&#xD;
&#xD;
          -  Joint or neuropathic pain&#xD;
&#xD;
          -  Current severe pain&#xD;
&#xD;
          -  Dispensed opioid analgesics within the last 45 days&#xD;
&#xD;
        To maintain the integrity of the study, we do not disclose all inclusion criteria to&#xD;
        potential participants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Inability to complete study visits over 14 weeks&#xD;
&#xD;
          -  Qualifying conditions for medical cannabis in NY that are likely to cause unique pain&#xD;
             syndromes&#xD;
&#xD;
          -  Terminal illness&#xD;
&#xD;
          -  Current or prior psychotic disorder&#xD;
&#xD;
          -  Current or prior buprenorphine or methadone treatment for opioid use disorder&#xD;
&#xD;
          -  Allergies to tapioca or coconut&#xD;
&#xD;
          -  Currently pregnant, planning to become pregnant within the next 3 months, or&#xD;
             breastfeeding&#xD;
&#xD;
          -  Condition that is considered by a pharmacist or medical provider to be a&#xD;
             contraindication to medical cannabis use (e.g. unstable cardiac arrhythmia or specific&#xD;
             drug-use interaction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Arnsten, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Arnsten, MD, MPH</last_name>
    <phone>718-944-3848</phone>
    <email>julia.arnsten@einsteinmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanna DiFrancesca</last_name>
    <phone>718-920-5763</phone>
    <email>giovanna.calderon@einsteinmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Health System</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Arnsten, MD, MPH</last_name>
      <phone>718-944-3848</phone>
      <email>julia.arnsten@einsteinmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Giovanna DiFrancesca</last_name>
      <phone>718-920-5763</phone>
      <email>giovanna.calderon@einsteinmed.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Julia H. Arnsten</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Marijuana</keyword>
  <keyword>Cannabis</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

